| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| AstraZeneca |
Mono-Ola1- |
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1) |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Ovarian Cancer |
| AstraZeneca |
D926FC00001 |
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) |
PERRAN FULDEN YUMUK (Prof.Dr.) |
Phase 1b |
Oncology |
Lung Cancer |
| inTUMO Therapeutics, Inc. |
INTUMO-002 |
A study to evaluate the safety and performance of Ionic Liquid on liver tumors in patients requiring tumor ablation A prospective, single-arm, single-center clinical trial |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Medical Device |
Oncology |
Liver Cancer |
| Regeneron Pharmaceuticals, Inc. |
R3767-ONC-2235 |
A Randomized, double blind Phase 2/3 study of Fianlimab (Anti-Lag-3 Antibody) in combination with Cemiplimab (Anti-PD-1 Antibody) versus Cemiplimab monotherapy in first-line treatment of patients with advanced non small cell lung cancer(NSCLC) WİTH TUMORS EXPRESSİNG PD-L1 ≥50% |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT116-01 |
LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Lung Cancer |
| GSK |
221530 |
A randomized, double-blind, placebo-controlled phase 3 study to evaluate dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma. |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase3 |
Oncology |
Head and Neck Cancer |
| Johnson and Johnson |
56021927PCR3015 |
Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Prostate Cancer |
| BioNTech SE |
BNT327-01 |
A Phase II, multi-site, open-label, parallel group trial of BNT327 in combination with chemotherapy for participants with untreated extensive-stage small-cell lung cancer and participants with previously treated small-cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT327-02 |
A Phase II, multi-site, randomized, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Breast Cancer |
| Amgen |
20230298 |
A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of subcutaneous tarlatamab in subjects with extensive stage small cell lung cancer (DeLLphi-308). |
PERRAN FULDEN YUMUK (Prof.Dr.) |
Phase 1b |
Oncology |
Lung Cancer |
| OncoC4 Inc. |
PRESERVE-003 |
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors. |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
V940-005 |
Phase 2, randomized, double-blind, placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with high-risk muscle-invasive urothelial carcinoma post-radical resection. |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Bladder Cancer |
| Merck Sharp & Dohme LLC |
MK-5684-004 |
A phase 3, randomized, open-label study of MK-5684 versus alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) that progressed on or after prior treatment with one next-generation hormonal agent (NHA). |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Pfizer Inc. |
C2321003 |
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (MEVPRO-2) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| GSK |
223559 |
A phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors. |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Cancer |
| BioNTech SE |
BNT327-03 |
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with firstline extensive-stage small-cell lung cance |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT327-06 |
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2/3 |
Oncology |
Lung Cancer |
| Pfizer Inc. |
C2321014 |
A phase 3, randomized, open-label study of pf-06821497 (mevrometostat) in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously treated with abiraterone acetate (MEVPRO-1) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Merck Sharp & Dohme LLC |
MK-3120-002 |
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants with Advanced Solid Tumors |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 1 |
Oncology |
Cancer |
| GSK |
223674 |
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| AstraZeneca |
D702AC00001 |
A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2 positive Gastric Cancer (ARTEMIDE-Gastric01) |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Gastric Cancer |
| BioNTech SE |
BNT327-07 |
A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemoimmunotherapy |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| MSD |
MK-1022-016-01 |
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Breast Cancer |
| Johnson and Johnson |
61186372PANSC2004 |
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 1/2 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT326-02 |
A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC). |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| AstraZeneca |
D7630C00001 |
Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Breast Cancer |
| Johnson and Johnson |
78278343PCR3003 |
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirectingAgent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for MetastaticCastration-resistant Prostate Cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| BioNTech SE |
BNT324-01 |
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 1 |
Oncology |
Lung Cancer |
| MSD |
MK5684-015 |
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 2 |
Oncology |
Cancer |
| Qilu Pharmaceutical Co., Ltd. |
Qilu QL2107-102 |
A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison with Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects with Resected Non-Small Cell Lung Cancer |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 3 |
Oncology |
Lung Cancer |
| BioNTech SE |
BNT323-03 |
A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Breast Cancer |
| AstraZeneca |
D9727C00001 |
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02 |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |
| Merck Sharp & Dohme LLC |
MK1084-014 |
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Cancer |
| Merck Sharp & Dohme LLC |
MK-2400-01A-01 |
A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02) |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Prostate Cancer |
| Merus N.V. |
MCLA-158-CL03 |
A Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Head and Neck Cancer |
| MSD |
V940-013 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013) |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
MK3475-01J |
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 2 |
Oncology |
Lung Cancer |
| AstraZeneca |
D702NC00001 |
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 3 |
Oncology |
Biliary Tract Cancer |
| ROCHE |
CO45813 |
A phase II, randomized, multicenter, open-label study evaluating the efficacy and safety of the combination of inavolisib plus enzalutamide versus physician's choice of arpi or docetaxel in patients with metastatic castration-resistant prostate cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 2 |
Oncology |
Prostate Cancer |
| Merck Sharp & Dohme LLC |
MK-6070-003 |
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer |
ŞEYDA GÜNDÜZ (Prof.Dr.) |
Phase 1b/2 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
MK6482-034 |
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK034) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Renal Cell Carcinoma |
| BioNTech SE |
BNT327-05 |
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease |
FATİH SELÇUKBİRİCİK (Prof.Dr.) |
Phase 3 |
Oncology |
Breast Cancer |
| Merck Sharp & Dohme LLC |
MK3120-003 |
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer |
DENİZ TURAL (Prof.Dr.) |
Phase 1 |
Oncology |
Bladder Cancer |
| BioNTech SE |
BNT326-01 |
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 1 |
Oncology |
Cancer |
| PlusVitech |
PVT-01 |
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Long-Term, High-Dose Aprepitant in Patients with Advanced or Refractory Non-Small Cell Lung Cancer |
ŞAHİN LAÇİN (Doç.Dr.) |
Phase 1/2 |
Oncology |
Lung Cancer |
| Merck Sharp & Dohme LLC |
MK-5684-003 |
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003) |
DENİZ TURAL (Prof.Dr.) |
Phase 3 |
Oncology |
Prostate Cancer |